Balyasny Asset Management
PHIO icon

Balyasny Asset Management’s Phio Pharmaceuticals PHIO Stock Holding History

Balyasny Asset Management’s Portfolio PHIO Stock Details PHIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-93
Closed -$6K – 3129
2022
Q3 		$6K Buy
+93
New +$7.04K ﹤0.01% 2693

Other funds holding PHIO

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Cetera Investment Advisers
Cetera Investment Advisers Schaumburg, Illinois $94B AUM 20.14% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Balyasny Asset Management's PHIO Position: Q4 2022 in Review

Balyasny Asset Management sold out of Phio Pharmaceuticals (PHIO) in Q4 2022, closing a stake of 93 shares — an estimated $6K sold.

Balyasny Asset Management first reported a position in PHIO in Q3 2022 and held it in 1 quarter. The position peaked at $6K in Q3 2022. 10 funds tracked by Wall St. Rank hold PHIO as of Q4 2022.

  • Balyasny Asset Management reported no remaining Phio Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Balyasny Asset Management sold 93 Phio Pharmaceuticals shares in Q4 2022, an estimated $6K.
  • Balyasny Asset Management first reported a position in Phio Pharmaceuticals in Q3 2022 and held it in 1 quarter.
  • Balyasny Asset Management's Phio Pharmaceuticals position peaked at $6K in Q3 2022.
  • 10 funds tracked by Wall St. Rank held Phio Pharmaceuticals as of Q4 2022.

Based on Balyasny Asset Management's 13F filing for Q4 2022, filed 14 Feb 2023.